keyword
MENU ▼
Read by QxMD icon Read
search

esophageal cancer chemotherapy

keyword
https://www.readbyqxmd.com/read/28514311/trends-in-esophageal-and-esophagogastric-junction-cancer-research-from-2007-to-2016-a-bibliometric-analysis
#1
Yan Miao, Ran Liu, Yuepu Pu, Lihong Yin
BACKGROUND: This study aimed to analyze the scientific outputs of esophageal and esophagogastric junction (EGJ) cancer and construct a model to quantitatively and qualitatively evaluate pertinent publications from the past decade. METHODS: Publications from 2007 to 2016 were retrieved from the Web of Science Core Collection database. Microsoft Excel 2016 (Redmond, WA) and the CiteSpace (Drexel University, Philadelphia, PA) software were used to analyze publication outcomes, journals, countries, institutions, authors, research areas, and research frontiers...
May 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28510799/practical-surgical-techniques-for-lymphadenectomy-along-the-right-recurrent-laryngeal-nerve-during-thoracoscopic-esophagectomy-in-the-prone-position
#2
Taro Oshikiri, Tetsu Nakamura, Yukiko Miura, Hiroshi Hasegawa, Masashi Yamamoto, Shingo Kanaji, Kimihiro Yamashita, Yoshiko Matsuda, Takeru Matsuda, Yasuo Sumi, Satoshi Suzuki, Yoshihiro Kakeji
BACKGROUND: In esophageal squamous cell cancer (SCC), lymphadenectomy along the right recurrent laryngeal nerve (RLN) is important for disease control. The metastatic rate was 33% and the 5-year overall survival rate of these patients was 33.3%,1 but the risk of RLN palsy increases.2 We reported a reliable new method ('Pincers Maneuver')3 for lymphadenectomy along the right RLN during thoracoscopic esophagectomy in the prone position (TEP), and hereby present our video, aimed at providing a complete and safe dissection...
May 16, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28501085/staging-in-esophageal-and-gastric-cancers
#3
REVIEW
Thomas Hayes, Elizabeth Smyth, Angela Riddell, William Allum
Gastric and esophageal tumors have a poor prognosis; approximately 15% of patients are alive at 10 years following diagnosis. Surgical resection plus adjunctive chemotherapy or chemoradiotherapy is curative in approximately 50% of patients with operable disease, but is also associated with significant morbidity. Therefore, accurate preoperative staging is required to spare patients unnecessary toxicity and futile surgery. This review evaluates the sensitivity and specificities of the modalities used to stage patients with gastroesophageal cancer...
June 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/28498235/hospital-minimally-invasive-surgery-utilization-for-gastrointestinal-cancer
#4
Meredith C Mason, Hop S Tran Cao, Samir S Awad, Farhood Farjah, George J Chang, Nader N Massarweh
OBJECTIVE: The aim of the study was to evaluate the impact of receiving care at high minimally invasive surgery (MIS)-utilizing hospitals BACKGROUND:: MIS techniques are used across surgical specialties. The extent of MIS utilization for gastrointestinal (GI) cancer resection and impact of receiving care at high utilizing hospitals is unclear. METHODS: This is a retrospective cohort study of 137,581 surgically resected esophageal, gastric, pancreatic, hepatobiliary, colon, and rectal cancer patients within the National Cancer Data Base (2010-2013)...
May 11, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28491289/recent-advances-in-preoperative-management-of-esophageal-adenocarcinoma
#5
REVIEW
Kazuto Harada, Dilsa Mizrak Kaya, Hideo Baba, Jaffer A Ajani
Esophageal cancer is an aggressive malignancy with increasing incidence, and the prognosis of patients treated by surgery alone remains dismal. Preoperative treatment can modestly prolong overall survival. Preoperative chemotherapy or chemoradiation is the standard of care for resectable esophageal cancer (greater than clinical stage I and less than clinical stage IV). One of the challenges is to predict complete response in the surgical specimen from preoperative therapy and to avoid surgery in some patients but also predict ineffectiveness of preoperative therapy if the tumor is resistant and avoid such therapies altogether...
2017: F1000Research
https://www.readbyqxmd.com/read/28480723/extrinsic-esophageal-compression-by-the-vertebral-body
#6
Laura Santos Santamaría, Mercedes Pérez Carreras, José Díaz-Tasende, Gregorio Castellano Tortajada
A 78-year-old woman with hypertension, diabetes, dyslipidemia, and revascularized ischemic heart disease was diagnosed with gastric adenocarcinoma in 2011, with suspected bilateral adrenal metastatic disease, and was treated with subtotal gastrectomy and palliative chemotherapy. A follow-up gastroscopy in 2015 identified a protruding, erosive mid-esophageal lesion suggestive of extrinsic compression or ulcerated submucosal lesion, which had not been described previously. Follow-up was advised, and the lesion persisted after three months...
May 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28477332/a-case-of-long-term-survival-after-surgical-resection-for-solitary-adrenal-recurrence-of-esophageal-squamous-carcinoma
#7
Nobuhiko Kanaya, Kazuhiro Noma, Tsuyoshi Okada, Naoaki Maeda, Shunsuke Tanabe, Kazufumi Sakurama, Yasuhiro Shirakawa, Toshiyoshi Fujiwara
BACKGROUND: Esophageal carcinomas are highly malignant tumors with a high frequency of lymph node and distant organ metastasis. Treatment for recurrent tumors is generally decided on an individual basis. Although multidisciplinary treatments involving chemotherapy, surgical resection, and radiation are performed, the prognosis remains poor. Here, we report a case of prolonged recurrence-free survival (38 months) after esophageal carcinoma surgery and subsequent laparoscopic adrenalectomy for right adrenal metastasis...
December 2017: Surgical Case Reports
https://www.readbyqxmd.com/read/28476443/phase-ii-study-of-preoperative-concurrent-chemoradiotherapy-with-oxaliplatin-for-locally-advanced-esophageal-cancer
#8
Jing-Wen Huang, Hui-Ling Yeh, Chung-Ping Hsu, Cheng-Yen Chuang, Jin-Ching Lin, Jai-Fu Lin, Chen-Fa Chang
BACKGROUND: We investigated preoperative concurrent chemoradiotherapy (CCRT) with oxaliplatin for locally advanced, potentially operative esophageal cancer in this Phase II study. METHODS: Between October 2009 and October 2011, 35 consecutive patients with newly diagnosed esophageal cancer clinical stage T3-4, N0-1, M0 were enrolled into this study. One dose of chemotherapy with oxaliplatin (35 mg/m(2)) on Day 1 and Day 2, leucovorin (200 mg/m(2)) on Day 1, and 5-fluorouracil [5-FU; 2400 mg/m(2) intravenously (i...
May 2, 2017: Journal of the Chinese Medical Association: JCMA
https://www.readbyqxmd.com/read/28475728/a-retrospective-comparison-of-neoadjuvant-chemoradiotherapy-regimens-for-locally-advanced-esophageal-cancer
#9
N N Sanford, P J Catalano, P C Enzinger, B L King, R Bueno, N E Martin, T S Hong, J Y Wo, H J Mamon
Preoperative chemoradiotherapy (CRT) with carboplatin/paclitaxel has been shown to increase survival in patients with esophageal cancer, including gastroesophageal junction (GE) junction cancer, over surgery alone; however, there have been no studies comparing the different neoadjuvant CRT regimens. We retrospectively evaluated the long-term results of trimodality therapy for patients with locally advanced esophageal cancer treated on several chemotherapy regimens. Between 1999 and 2014, 215 patients with locally advanced esophageal cancer underwent neoadjuvant CRT followed by surgical resection...
July 1, 2017: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/28475725/neoadjuvant-versus-adjuvant-chemoradiation-for-stage-ii-iii-esophageal-squamous-cell-carcinoma-a-single-institution-experience
#10
Y Chen, D Hao, X Wu, W Xing, Y Yang, C He, W Wang, J Liu, J Wang
Esophageal cancer is the eighth most common cancer worldwide. It is the fourth most common cause of cancer death in China and esophageal squamous cell carcinoma (ESCC) is the most prevalent histologic type. Many clinical trials have explored the value of neoadjuvant or adjuvant chemoradiation therapy in potentially resectable ESCC; however, these studies have produced conflicting results. This retrospective study was performed to investigate whether patients with resectable stage II/III ESCC should receive neoadjuvant or adjuvant therapy in addition to surgery...
July 1, 2017: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/28475724/neoadjuvant-chemoradiotherapy-with-concurrent-cisplatin-5-fluorouracil-is-associated-with-increased-pathologic-complete-response-and-improved-survival-compared-to-carboplatin-paclitaxel-in-patients-with-locally-advanced-esophageal-cancer
#11
K R Haisley, K D Hart, N Nabavizadeh, K G Bensch, G M Vaccaro, C R Thomas, P H Schipper, J G Hunter, J P Dolan
Trimodal therapy consisting of neoadjuvant chemoradiation followed by esophagectomy has become the standard of care in North America for locally advanced esophageal cancer. While cisplatin/5-fluorouracil has been a common concurrent chemotherapy regimen since the 1980s, its utilization has declined in recent years as the Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS) trial regimen of carboplatin/paclitaxel has become widely adopted. The efficacy of the CROSS regimen compared to alternate chemotherapy choices, however, has rarely been evaluated when each is used as a component of a trimodal treatment approach...
July 1, 2017: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/28472560/nedaplatin-and-irinotecan-with-concurrent-thoracic-radiotherapy-followed-by-docetaxel-consolidation-in-patients-with-locally-advanced-non-small-cell-lung-cancer
#12
Fumihiro Oshita, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, Kouzo Yamada, Yuko Nakayama
OBJECTIVE: We conducted a phase II study of nedaplatin (NP) and irinotecan (CPT) with concurrent thoracic radiotherapy (TRT) followed by docetaxel for locally advanced non-small cell lung cancer (NSCLC) to determine the safety and efficacy of the treatment. Patients with stage IIIA or IIIB NSCLC were treated with 3 cycles of chemotherapy comprising NP at 50 mg/m(2) and CPT at 50 mg/m(2) on days 1 and 8 every 4 weeks with concurrent TRT (2 Gy/day, total 66 Gy) followed by 3 cycles of docetaxel at 60 mg/m(2) on day 1 every 3 weeks...
May 2017: Journal of Experimental Therapeutics & Oncology
https://www.readbyqxmd.com/read/28472195/safety-of-endoscopy-in-cancer-patients-on-antiangiogenic-agents-a-retrospective-multicenter-outcomes-study
#13
Toufic Kachaamy, Digant Gupta, Persis Edwin, Pankaj Vashi
BACKGROUND/AIMS: The use of antiangiogenic agents (AAs) in cancer treatment has increased because they offer survival benefit in combination with cytotoxic chemotherapy. Given their potential to cause gastrointestinal (GI) perforation and bleeding, it is currently recommended that AAs be held for 28 days before and after surgery. However, there are no specific guidelines which address their use around endoscopic procedures because data regarding the safety of endoscopy in cancer patients while on AAs is scarce despite the fact that these patients often require endoscopy...
2017: PloS One
https://www.readbyqxmd.com/read/28471547/-comprehensive-therapeutic-strategy-for-localized-esophageal-cancer-second-part-interest-of-multimodal-approaches-with-or-without-surgery
#14
D Van Daele, P Honoré, J Collignon, M Polus, C Loly, E Mutijima, A De Roover, P A Coucke, E Louis, P Martinive
In recent years, the treatment of esophagus cancer has been completely changed, thus competing the dogma of surgery as the cornerstone treatment. Multimodality treatments as radio-chemotherapy directly followed by surgery, or delayed surgery, significantly improve patient survival compared to surgery alone. Neoadjuvant radiochemotherapy is associated with a higher complete pathologic response rate and improved survival compared to chemotherapy alone. Immediate surgery after radio-chemotherapy is challenged for patients who present a complete clinical response, especially in case of squamous cell carcinoma...
April 2017: Revue Médicale de Liège
https://www.readbyqxmd.com/read/28467775/simultaneous-integrated-boost-intensity-modulated-radiotherapy-for-locally-advanced-non-small-cell-lung-cancer-in-chinese-population-a-retrospective-study
#15
Yujin Xu, Xiao Zheng, Xue Bai, Pu Li, Honglian Ma, Jin Wang, Xiao Hu, Ming Chen
OBJECTIVES: To evaluate the clinical efficacy and toxicity of simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) for patients with locally advanced non-small cell lung cancer (NSCLC). RESULTS: All patients completed definitive radiotherapy and 74 (85.1%) patients administrated platinum-based chemotherapy. The median radiation dose was 50.4Gy to PTV and 64.4 Gy simultaneously to the PGTV. The overall response rate (ORR) was 57.5% (50/87). The median duration of follow up was 24...
April 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/28465312/a-comparative-analysis-of-whole-genome-sequencing-of-oesophageal-adenocarcinoma-pre-and-post-chemotherapy
#16
Ayesha Noorani, Jan Bornschein, Andy G Lynch, Maria Secrier, Achilleas Achilleos, Matthew Eldridge, Lawrence Bower, Jamie M J Weaver, Jason Crawte, Chin-Ann Ong, Nicholas Shannon, Shona MacRae, Nicola Grehan, Barbara Nutzinger, Maria O'Donovan, Richard Hardwick, Simon Tavaré, Rebecca C Fitzgerald, Rachael Fels Elliott, Paul A W Edwards, Xiaodun Li, Hamza Chettouh, Gianmarco Contini, Eleanor Gregson, Sebastian Zeki, Laura Smith, Zarah Abdullahi, Rachel de la Rue, Ahmad Miremadi, Shalini Malhotra, Mike L Smith, Jim Davies, Charles Crichton, Nick Carroll, Peter Safranek, Andrew Hindmarsh, Vijayendran Sujendran, Richard Turkington, Stephen J Hayes, Yeng Ang, Shaun R Preston, Sarah Oakes, Izhar Bagwan, Vicki Save, Richard J E Skipworth, Ted R Hupp, J Robert O'Neill, Olga Tucker, Andrew Beggs, Philippe Taniere, Timothy J Underwood, Fergus Noble, Jack Owsley, Hugh Barr, Neil Shepherd, Oliver Old, Jesper Lagergren, James Gossage, Andrew Davies, Fuju Chang, Janine Zylstra, Grant Sanders, Richard Berrisford, Catherine Harden, David Bunting, Mike Lewis, Ed Cheong, Bhaskar Kumar, Simon L Parsons, Irshad Soomro, Philip Kaye, Laurence Lovat, Rehan Haidry, Victor Eneh, Laszlo Igali, Michael Scott, Shamila Sothi, Sari Suortamo, Suzy Lishman
The scientific community has avoided using tissue samples from patients that have been exposed to systemic chemotherapy to infer the genomic landscape of a given cancer. Esophageal adenocarcinoma is a heterogeneous, chemoresistant tumor for which the availability and size of pretreatment endoscopic samples are limiting. This study compares whole-genome sequencing data obtained from chemo-naive and chemo-treated samples. The quality of whole-genomic sequencing data is comparable across all samples regardless of chemotherapy status...
May 2, 2017: Genome Research
https://www.readbyqxmd.com/read/28464264/concurrent-chemoradiotherapy-with-or-without-surgery-for-patients-with-resectable-esophageal-cancer-an-analysis-of-the-national-cancer-data-base
#17
Kushal B Naik, Yuan Liu, Michael Goodman, Theresa W Gillespie, Allan Pickens, Seth D Force, Conor E Steuer, Taofeek K Owonikoko, Suresh S Ramalingam, Kristin Higgins, Jonathan J Beitler, Dong M Shin, Field F Willingham, Bassel El-Rayes, Jerome C Landry, Felix G Fernandez, Nabil F Saba
BACKGROUND: Patients with resectable esophageal cancer (rEC) are managed with either concurrent chemoradiotherapy followed by surgery (CRSx) or concurrent chemoradiotherapy alone (cCR). To the authors' knowledge, there is insufficient evidence comparing the overall survival of patients treated with these 2 options. METHODS: The National Cancer Data Base was queried for rEC cases diagnosed from 2003 through 2011. Patients with previous cancers, cervical rEC, clinical stage T1N0 disease, or metastasis were excluded...
May 2, 2017: Cancer
https://www.readbyqxmd.com/read/28463955/capilliposide-c-sensitizes-esophageal-squamous-carcinoma-cells-to-oxaliplatin-by-inducing-apoptosis-through-the-pi3k-akt-mtor-pathway
#18
Zhipeng Shen, Lixia Xu, Juan Li, Ni Zhang
BACKGROUND Although platinum-based chemotherapy is the most effective strategy for esophageal cancer, toxicity and drug resistance limit the dose administration and the application of chemotherapy. Capilliposide C (CPS-C) is isolated from the Chinese herb Lysimachia capillipes Hemsl and is approved to be effective against carcinomas. However, the activity of CPS-C against esophageal cancer remains unclear. The present study was conducted to assess the chemosensitizing effects of CPS-C for enhancing the therapeutic efficacy of oxaliplatin in esophageal squamous carcinoma cells and explore the underlying mechanism...
May 2, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28461255/improved-overall-survival-with-aggressive-primary-tumor-radiotherapy-for-patients-with-metastatic-esophageal-cancer
#19
David M Guttmann, Nandita Mitra, Justin Bekelman, James M Metz, John Plastaras, Weiwei Feng, Samuel Swisher-McClure
OBJECTIVES: The aim of this study was to characterize utilization and survival outcomes associated with primary tumor-directed radiotherapy (PTDRT) in patients with newly diagnosed metastatic esophageal cancer. METHODS: We conducted an observational cohort study using the National Cancer Data Base to evaluate patients with newly diagnosed metastatic esophageal cancer between 2004 and 2012. Overall survival outcomes after treatment with chemotherapy plus conventional palliative dose radiotherapy (<5040 cGy), chemotherapy plus definitive dose radiotherapy (≥5040 cGy), or chemotherapy alone were compared by using Cox proportional hazards models with inverse probability of treatment weighting using the propensity score...
April 28, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28459652/handgrip-strength-is-associated-with-treatment-modifications-during-neoadjuvant-chemoradiation-in-patients-with-esophageal-cancer
#20
Patty Lakenman, Karen Ottens-Oussoren, Jill Witvliet-van Nierop, Donald van der Peet, Marian de van der Schueren
RATIONALE: It has been shown that early nutrition intervention improves nutrition status (NS) and treatment tolerance in patients with esophageal cancer. However, it remains unknown whether pretreatment parameters of NS are associated with treatment modifications (TMs) during neoadjuvant chemoradiation (CR) in patients who are intensively nutritionally supervised during treatment. METHODS: All outpatients with esophageal cancer who were scheduled for CR in the VU medical center from 2006-2015 were included...
April 1, 2017: Nutrition in Clinical Practice
keyword
keyword
40930
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"